Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals (NASDAQ: RIGL) has announced the granting of inducement awards to new employees under NASDAQ Listing Rule 5635(c)(4). The company granted a total of 23,075 stock options and restricted stock units to 10 non-executive employees. These equity awards will vest over a four-year period with a one-year cliff.
Rigel, founded in 1996 and based in South San Francisco, is a biotechnology company focused on developing therapies for hematologic disorders and cancer.
Rigel Pharmaceuticals (NASDAQ: RIGL) ha annunciato la concessione di premi di incentivazione a nuovi dipendenti ai sensi della Regola NASDAQ 5635(c)(4). La società ha assegnato un totale di 23.075 opzioni su azioni e unità azionarie vincolate a 10 dipendenti non dirigenti. Questi premi azionari matureranno nell'arco di quattro anni con un periodo di vesting iniziale di un anno.
Rigel, fondata nel 1996 e con sede a South San Francisco, è un'azienda biotecnologica focalizzata sullo sviluppo di terapie per disturbi ematologici e il cancro.
Rigel Pharmaceuticals (NASDAQ: RIGL) ha anunciado la concesión de premios de incentivo a nuevos empleados conforme a la Norma de Listado NASDAQ 5635(c)(4). La compañía otorgó un total de 23,075 opciones sobre acciones y unidades restringidas de acciones a 10 empleados no ejecutivos. Estas concesiones de acciones se consolidarán durante un período de cuatro años con un período inicial de un año.
Rigel, fundada en 1996 y con sede en South San Francisco, es una empresa biotecnológica centrada en desarrollar terapias para trastornos hematológicos y cáncer.
Rigel Pharmaceuticals (NASDAQ: RIGL)는 NASDAQ 상장 규칙 5635(c)(4)에 따라 신입 직원들에게 유인 보상을 부여했다고 발표했습니다. 회사는 10명의 비임원 직원에게 총 23,075주의 스톡옵션 및 제한 주식 단위를 부여했습니다. 이 주식 보상은 1년 클리프 기간을 포함한 4년간에 걸쳐 권리가 취득됩니다.
1996년에 설립되어 사우스 샌프란시스코에 본사를 둔 Rigel은 혈액 질환 및 암 치료제 개발에 주력하는 생명공학 회사입니다.
Rigel Pharmaceuticals (NASDAQ : RIGL) a annoncé l’attribution de primes d’incitation à de nouveaux employés conformément à la règle NASDAQ 5635(c)(4). La société a accordé un total de 23 075 options d’achat d’actions et unités d’actions restreintes à 10 employés non cadres. Ces attributions d’actions seront acquises sur une période de quatre ans avec un cliff d’un an.
Fondée en 1996 et basée à South San Francisco, Rigel est une entreprise de biotechnologie spécialisée dans le développement de thérapies pour les troubles hématologiques et le cancer.
Rigel Pharmaceuticals (NASDAQ: RIGL) hat die Gewährung von Anreizprämien an neue Mitarbeiter gemäß NASDAQ-Listing-Regel 5635(c)(4) bekannt gegeben. Das Unternehmen gewährte insgesamt 23.075 Aktienoptionen und Restricted Stock Units an 10 nicht geschäftsführende Mitarbeiter. Diese Aktienvergütungen werden über einen Zeitraum von vier Jahren mit einer einjährigen Sperrfrist vesten.
Rigel, gegründet 1996 und mit Sitz in South San Francisco, ist ein Biotechnologieunternehmen, das sich auf die Entwicklung von Therapien für hämatologische Erkrankungen und Krebs spezialisiert hat.
- None.
- None.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302498479.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
What inducement grants did Rigel Pharmaceuticals (RIGL) announce in July 2025?
How many employees received inducement grants from Rigel (RIGL) in July 2025?
What is the vesting schedule for Rigel's (RIGL) July 2025 inducement grants?
What is Rigel Pharmaceuticals' (RIGL) main business focus?
